World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 4
Page: 84-100

REVIEW ARTICLE ON TRP CHANNELS IN PAIN MANAGEMENT SYSTEM

Ritik Choudhary[1], Rajdeep Kaur*[2], Dr. Jyoti Gupta[3], Nisha Devi[2]

[1]Research Scholar, IEC University, IEC School of Pharmacy, Kalujhanda, Baddi, Solan, Himachal Pradesh, 174103.

[2]Associate Professor IEC School of Pharmacy, IEC University, Kalujhanda, Baddi, Solan, Himachal Pradesh, 174103.

[3]HOD, IEC School of Pharmacy, IEC University, Kalujhanda, Baddi, Solan, Himachal Pradesh, 174103.

Article Received: 5 February 2026 | | ***Article Revised: 26 February 2026*** | | ***Article Accepted: 18 March 2026***

***Corresponding Author: Rajdeep Kaur**
Associate Professor IEC School of Pharmacy, IEC University, Kalujhanda, Baddi, Solan, Himachal Pradesh, 174103.
DOI: https://doi.org/10.5281/zenodo.19332380

How to cite this Article: Ritik Choudhary, Rajdeep Kaur, Dr. Jyoti Gupta, Nisha Devi (2026) REVIEW ARTICLE ON TRP CHANNELS IN PAIN MANAGEMENT SYSTEM. World Journal of Pharmaceutical Science and Research, 5(4), 84-100.

ABSTRACT

The transient receptor potential (TRP) channels, TRPV1, TRPA1, and TRPM8 in particular, are chief molecular sensors for pain and chronic pain signal detection. As polymodal cation channels, they locally detect thermal, chemical, and mechanical stimuli in sensory neurons and hence contribute to nociceptive, nociplastic, and neuropathic pain conditions such as arthritis, diabetic neuropathy, and migraines. When dysregulated, they become linked to disorders like overactive bladder, cancer, and inflammation. TRPV1 is heat and capsaicin receptor that integrate painful stimuli and initiate neurogenic inflammation; resiniferatoxin, a TRPV1 agonist, is currently on trial for cancer pain, whereas, TRPV1 antagonists (e.g., NEO6860, mavatrep) often fail due to hyperthermia, burns, or less efficacy. TRPA1 reacts to irritants and oxidative stress while its antagonist, GRC-17536, is effective in phase II diabetic neuropathy studies but discontinued due to pharmacokinetic liabilities. TRPM8 is a cold sensor and a potential migraine target; antagonist like PF-05105679 reduce cold pain but cause mild side effects, whereas, agonists are useful for dry eye. Among the problems which have delayed clinical translation are species differences, poor pharmacokinetics, as well as on-target toxicities. Through their modulation, it is possible to achieve a therapeutic breakthrough in pain conditions that are currently not adequately treated. Efforts are being made in creating thermoneutral antagonists, siRNAs, and novel derivatives.

KEYWORDS: Pain, Pain and its types, Pathophysiology of pain, TRP Channels work with Pain, TRP Channels Causes Disease, TRP Channels as Drug Target, Clinical Application of TRP Channels, Challenges of TRP channels, Future Directions, Conclusion.

INTRODUCTION

Pain is a distressing sensory and emotional experience related to the actual or potential tissue damage. Pain is not only a physical feeling but it also has emotional and psychological aspects according to the International Association for the Study of Pain. It is a warning system that signals the body about the presence of injury or dangerous stimuli like heat, pressure, inflammation or chemical irritation.

The transient receptor potential (TRP) superfamily is a collection of nonselective cation channels that act as molecular sensors in response to changes in the intracellular and extracellular environments.[1,3] These are integral membrane proteins that have been conserved throughout evolution. Molecular sensing, coincidence detection, and cellular signal integration are made easier by the polymodality of many TRP channels. From single-cell green algae to human systems, these channels have been found in a wide variety of eukaryotes. In addition to preserving homeostasis, TRP channels have been revealed to be involved in a number of biological processes related to thermo-, chemo-, photo-, and mechanosensation.[4-6]

Based on sequence similarities, TRP channels in mammals are classified into six subfamilies: TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), TRPML (mucoliptin), and TRPP (polycystin).[7,8] The downstream activation of phospholipase C cascades via G protein-coupled receptors (GPCRs) initiates mammalian TRPC channels, which are non-selective Ca2+ permeable cation channels. Based on amino acid homologies, these channels are a collection of seven different proteins that are separated into four subgroups: TRPC2, TRPC3,6,7, TRPC1, and TRPC4/5.[9,10]

Dysregulation of Transient Receptor Potential (TRP) channels has been increasingly recognized as a contributing factor in the development of multiple disorders affecting different organ systems such as Overactive bladder (TRPV1), obesity (TRPV4 and TRPM5), chronic cough (TRPV1, TRPV1) and pain,[11-12] diabetes (TRPV1, TRPM4), chronic obstructive pulmonary disease (TRPV4), cardiac hypertrophy (TRPC6), dermatological disorders (TRPV3), cancer (TRPV6, TRPV2, and TRPM8), and familial Alzheimer's disease (TRPM7) have all been linked to TRP channel dysfunction.[13,14]

Thus, regulating these hyperactive TRP channels by antagonist mediators may prove to be clinically favorable.[15,16] Besides, loss-of-function mutation like loss of TRPML1 function (type-IV mucolipidosis) is also alarming.[17,18] The regulation of these hyperactive TRP channels using antagonist mediators may, therefore, be of clinical advantage. Furthermore, a loss-of-function mutation such as a loss of TRPML1 function (type-IV mucolipidosis) is also very dangerous.[19,20]

Transient Receptor Potential (TRP) channels are one of the main players in how the body senses and reacts to pain. They are ion channels that exist mainly in sensory neurons, especially in nociceptors, where they serve as the molecular detectors of various painful stimuli such as hot, cold, mechanical pressure, or chemical irritants. Upon activation by such stimuli, TRP channels let calcium (Ca^{2+}) and sodium (Na^{+}) ions into the neuron, causing depolarization and the production of electrical signals. These signals then travel via the peripheral nerves to the spinal cord and brain, where they are recognized as pain.

When the tissues are damaged or inflamed, inflammatory substances sensitize TRP channels, reducing their activation threshold and thus causing intensification of pain-related phenomena such as hyperalgesia and allodynia.

Pain

Pain is the body's warning system. It signals that something is wrong. In fact, it's a complicated experience that includes both the physical feeling and the emotions that go along with it.

This means that pain is not only about feeling hurt but also about the emotional and psychological effects that come with it. Pain is a symptom of many different types of illness and injury. It can also be a warning sign that helps us avoid further harm. For example, the pain we feel when we touch something hot makes us pull our hand away quickly so that we don't burn ourselves.

Pain and Its Types

Chronic Pain is a major symptom of many illnesses and it severely disables sufferers and drastically lowers their quality of life. At present, pain management is very limited and this is a global health challenge that remains unmet.[21] The difficulty in understanding and treating pain has led to the overuse of morphine/opioids which has resulted in very serious side effects.[22,23] Pain can essentially be divided into 3 types: nociceptive, nociplastic and neuropathic. Nociceptive pain represents the majority of chronic pain and it mainly results from neuronal cascades activation. The major conditions under this category are spinal pain and arthritis.[24]

Nociplastic pain results from the pain signal processing mechanism malfunction without there being any tissue damage or disease. Neuropathic pain accounts for around 15% to 25% of the cases of chronic pain and it is caused by an injury or disease to the somatosensory nervous system. It is usually accompanied by sensory anomalies such as allodynia and numbness. It also comprises postherpetic neuralgia, diabetic neuropathy and radiculopathy.[25,26] Both allodynia and hyperalgesia are symptoms of the disorder and they might be beneficial adaptations designed to prevent damage to the susceptible organs. Nevertheless, the increased pain sensitivity may go on for a long time even after the pain's initial cause has disappeared.[27]

To solve the problems related to pain management and to improve the level of patient lives, it is necessary to have a more in-depth knowledge of the mechanisms that regulate the in- – pain so that new methods of treatment can be developed.

Nociceptive Pain

The production of nociceptive pain is carried out by special nerve endings known as nociceptors which have a significantly.[28]

Type	Description	Examples
Somatic	From musculoskeletal or skin tissues; sharp, localized.	Sprains, cuts, bone fractures.
Visceral	From internal organs; poorly localized, cramping.	Appendicitis, ischemia.
Radicular	Nerve root irritation; radiates along nerve path.	Herniated disc pain down leg.

higher activation threshold when compared to those that are involved in the sensation of taste, smell, sound, and light. Nociceptors are extremely sensitive to noxious heat stimuli, chemical irritants, extreme mechanical stimuli, and those stimuli that can potentially cause tissue damage. When the stimuli reach the threshold, they trigger the nociceptive

nerve terminals to generate action potentials, which later are transmitted and perceived as pain signals.[29] The stimuli are converted into electrical signals and transduced into action potentials with the assistance of several channels and receptors located on the free synaptic terminals and nerve endings. Together as a class of cation-permeable poly-modal channels involved in cell depolarization, TRP channels are related to various physiological functions, including pain perception.[30,31]

NOCIPLASTIC PAIN

In nociplastic pain, it is the distorted nociception that causes the problem. Nociception refers to the processes involved in sensing and transmitting pain to the brain. Central sensitization is the most important pathophysiological mechanism of nociplastic pain. Central sensitization refers to the increased responsiveness of neurons in the spinal cord and brain. Peripheral tissues send pain signals via nociceptors to the spinal cord and brain where pain is perceived under normal circumstances. After that, the brain sends descending inhibitory pathways to regulate and suppress excessive pain signals. The balance between excitation and inhibition in nociplastic pain is compromised.[32] Thus, excitatory pathways are going to be overactive while inhibitory pathways get weaker. Consequently, pain from a harmless stimulus will be very severe, and allodynia develops. Moreover, stimuli that would normally be painful might become even more painful, a condition called hyperalgesia. It means that the nervous system is simply "over-amplified" and keeps on sending pain signals even though the body has already been healed from the tissue damage.

There are many cellular changes that accompany central sensitization amongst which increased release of excitatory neurotransmitters like glutamate in the spinal cord is the hallmark. Hence, neurons are firing more frequently becoming hyperexcitable.[33] Accordingly, pain transmission pathways may be potentiated due to the enhanced effectiveness of NMDA receptors. Moreover, the effectiveness of inhibitory neurotransmitters like gamma-aminobutyric acid (GABA) and serotonin is reduced. Neuroplasticity, changes in the structure and function of neural circuits over time, helps to maintain and stabilize the pain pathways. Brain scans show that there is an aberrant functioning of the brain regions responsible for processing pain, emotion, and cognition such as the prefrontal cortex, insula, and anterior cingulate cortex. All these findings point to the fact that nociplastic pain can be considered as pain with sensory and emotional facets.[34]

NEUROPATHIC PAIN

Neuropathic pain is a type of pain that may arise when there has been damage done to nerves in the periphery, spinal cord, or brain. It may be a sequel of trauma, infection, metabolic changes, autoimmune diseases, or neurodegenerative disorders. Diabetes is one of the diabetes-related complications.[35] In addition to that, the frequent occurrences of neuropathic pain are herpes zoster virus infection, cerebrovascular stroke, internal spinal cord damage, the autoimmune disorder multiple sclerosis, and nerve damage resulting from chemotherapy. The nervous system fundamentally is the main medium of sensing stimuli and thus any damage to it can cause the generation of aberrant and overly sustained pain signals.[36]

Neuropathic pain presents the consequence of interactions of, among others, peripheral and central mechanisms. A broad range of structural and functional changes takes place in the nerve with the injury. One such change is that destroyed nerve fibers are capable of generating impulses by themselves in the absence of any external stimulus. The presence of this abnormal spontaneous activity will be reflected in the symptoms of burning or shooting pain which a patient is experiencing in the absence of a provocation.[37]

Pathophysiology of Pain

The pathophysiology of pain is made up of a number of stages during which the nervous system recognizes, sends, and understands harmful stimuli. These stages are transduction, transmission, modulation, and perception.

1. Transduction

Transduction starts the pain pathway. During this phase, damaging stimuli like heat, mechanical, or chemical factors cause sensory receptors, nociceptors that are a special type of receptors, to create electrical signals.[38] They are found in the skin, muscles, joints, and organs. When the tissues get hurt, chemicals like prostaglandins, bradykinin, histamine, serotonin, and cytokines are produced. These substances trigger nociceptors and start the process of sending electrical signals. Ion channels such as TRPV1 often participate in detecting heat and chemical stimuli at this stage.[39]

2. Transmission

Transmission is a term used to describe the sending of pain stimuli from the place of injury to the brain. After the pain receptors are turned on, the electrical signals go along the nerves to the spinal cord. Here are the two main types of nerve fibers involved:

a) A-delta fibers that convey fast, sharp, and accurately localized pain.
b) C fibers that convey slow, dull, and aching pain.[40,41]

The pain signals make their way into the dorsal horn of the spinal cord and later climb the ascending pathways like spinothalamic tract to the brain, and in particular the thalamus and cerebral cortex.

3. Modulation

Modulation is the mechanism that determines whether pain signals in the spinal cord and brainstem get intensified or suppressed. At this point, pain transmission is modulated by neurotransmitters as well as endogenous analgesic substances.[42] The body does its part by producing and releasing natural painkillers like endorphins, enkephalins, and serotonin which instantly block the transmission of pain signals. The brain through descending pathways can also stop the relay of pain signals by affecting the spinal cord neurons.[43]

4. Perception

The brain interprets the pain signals and produces a conscious pain experience as the last step which is perception. The main sites for this process are thalamus, somatosensory cortex, limbic system, and frontal cortex. Emotional state, attention, cultural background, and past experiences are some of the factors capable of influencing how pain is recognized and interpreted.[44]

TRP Channels

Transient Receptor Potential (TRP) channels represent a large family of non-selective cation channels found primarily in the plasma membrane of various cell types, notably sensory neurons. These channels are key players in sensing both external and internal changes such as temperature, mechanical forces, pH alterations, changes in osmotic pressure, and exposure to chemical irritants.[45] TRP channels control the flux of ions including calcium (Ca^{2+}), sodium (Na^{+}), and less frequently magnesium (Mg^{2+}) through the cell membrane. Hence, they are involved in a wide range of physiological functions like the perception of pain, the inflammatory process, the maintenance of body temperature, and intracellular signaling. Some major members of this channel family are TRPV1, TRPA1, and TRPM8.[46]

How the TRP Channels Work with Pain

Transient receptor potential ion channels, or TRP channels for short, are a group of sensory ion channels mainly found in nociceptive neurons. These neurons respond to potentially harmful stimuli by converting the stimuli physically and chemically into electrical signals. The brain perceives these signals as pain. Different subtypes of TRP channels are implicated in pain sensation through diverse mechanisms.

Mechanism of action

1. TRPV1

TRPV1 is highly characterized among the TRP channels that cause pain. It can be triggered by heat at temperatures of approximately 43°C and above, acid, capsaicin, a component of hot chili peppers, and inflammatory mediators.[47]

The activation of this channel results in the opening of the channel, leading to the entry of Ca^{2+} and Na^{+} into the sensory neuron. This influx of ions depolarizes the membrane and generates action potentials. These signals are then sent to the spinal cord and brain. Inflaming conditions release different substances that sensitize TRPV1 and are responsible for pain hyperalgesia.[48]

2. TRPA1

TRPA1 functions as a detector for chemical irritants, toxins in the environment, mustard oil, and oxidative stress. It localizes with TRPV1 both being involved in sensing noxious stimuli. Upon activation, the channel allows Ca^{2+} and Na^{+} ions into the neuron leading to its depolarization and a subsequent pain signal generation. TRPA1 is an important mediator in inflammatory and neuropathic pain.[49,50]

3. TRPM8

TRPM8 channels respond mainly to cool temperatures and to cooling products like menthol. The activation of these channels results in the movement of Ca^{2+} and Na^{+} ions into the neuron, thereby sending the signals that the brain interprets as cold or cold-induced pain. Under pathological conditions, TRPM8 is implicated in cold hypersensitivity a feature of neuropathic pain.[51]

TRP channels causes diseases

1. TRPV1

This gene encodes the protein TRPV1. It is a protein that majorly found in sensory neurons and is triggered by heat, acid, and capsaicin. An excessive activation or sensitization of TRPV1 is the main cause of chronic pain, inflammatory pain, diabetes, and chronic cough. In cases of inflammation, agents like prostaglandins raise TRPV1 sensitivity, hence increasing the sensation of pain and the development of chronic pain.[52]

2. TRPM8

The cold-sensing receptor TRPM8 gets activated at very low temperatures or even by the cooling sensation of menthol. It has been found that malfunctioning of the TRPM8 channel is associated with the development of neuropathic pain and prostate cancer. In the latter case, it also seems to affect the progression of tumor cells.[53]

.

3. TRPA1

TRPA1 responds to chemicals present in cigarette smoke and pollution to cause persistent coughing, asthma, and chronic obstructive pulmonary diseases. TRPA1 activation in trigeminal neurons is associated with migraine headaches and its stimulation in primary afferent nerves of the skin leads to itching and inflammatory skin disorders.[54]

TRP CHANNELS AS DRUG TARGET

Although the TRP channels are highly conserved evolutionally, their sensitivity to extrinsic stimuli shows extraordinary species-linked differences. Because of this, most of the recent work has been focused on understanding the clinical ramifications of TRP channels in different diseases.[55] Results of the research have shown that 4 types of TRPV channels (TRPV1-4) are mostly present in the afferent nociceptors, pain-sensing neurons, and are involved in the transduction of thermal and chemical stimuli. Most notably, TRPV1-3, and TRPM8 are primarily responsible for detecting changes in temperature, whereas TRPA1 and TRPV4 contribute to the sensation of mechanical stretch or pressure. Consequently, ion channels involved in thermal, chemical, and mechanical sensory perceptions are, thus, potential therapeutic targets for alleviating chronic pain. Ligands interact with these channels (TRPV1, TRPA1, and TRPM8) through covalent linkages and each of them modulates the channels in different ways. A majority of the ligands in the clinical trial pipeline have been unsuccessful due to their poor pharmacodynamic and pharmacokinetic properties.[56,57]

TRPV1

TRPV1 is an exemplar of a TRP channel that shows diversity in function and expression. It is mostly found on primary sensory neurons where it plays a major role as a potent inducer of neurogenic inflammation and a key integrator of painful stimuli. The sensory neurons that communicate with the brain via TRPV1 are linked to mechanisms of itching and sensing heat. The necessary work of David Julius with capsaicin as a pain inducer extracted from nature has allowed us to find the TRPV1 ion channel acting as a heat-activated nociceptor in the peripheral nervous system.[58]

The Royal Swedish Academy of Sciences has particularly recognized this break- through discovery by awarding the 2021 Nobel Prize in Physiology and Medicine to David Julius. Neuronal TRPV1 in the viscera triggers reflexes such as intestinal peristalsis, cough, micturition, and heart rate. Brain nuclei and non-neuronal cells also express TRPV1 but at lower levels. Different kinetics of the receptor activation have been made with TRPV1 agonists, MRD-652 and Olvanil (NE19550).[59] Animals with pain both compounds resulted promising, anyway, their clinical manifestations are yet to be carried out. Resiniferatoxin, an ultra- potent capsaicin analog, is in the phases of clinical trials for checking its efficacy as a permanent analgesia in cancer subjects with severe intractable pain, and in chronic osteoarthritic pain. It has cervical been tested in a small-scale study involving females with cancer, and the outcomes have revealed promising results.48 In the latest research vitamin D has been shown to function as a partial agonist of TRPV1 at physiologically relevant free plasma levels.[60,61]

At the same time, a number of TRPV1 antagonists have been also unravelled that have been clinically involved as lead candidates. Nevertheless, their responses have been different in pain preclinical models. A handful of them were demonstrated to be effective in neuropathic and inflammatory pain models whereas the rest efficacies were limited only to inflammatory pain models.[62] Most of the first-generation TRPV1 antagonists caused several on-target adverse effects, which made them to be discontinued from clinical trials. GSK's SB-705498 was the first TRPV1 antagonist that moved to clinical development in 2005 and later it failed to produce the desired results. New results, however, have

revealed (S)-N-(3-isopropylphenyl)-2-(5-phenylthiazol-2-yl) pyrrolidine-1- carboxamide as a potent and brain-penetrant TRPV1 antagonist.[63]

Mechanism of action

TRPV1 gets switched on by heat (over 43°C), capsaicin, protons (low pH), and inflammatory agents. When triggered, it opens the ion channel, leading to Ca^{2+} and Na^{+} ions flowing into the sensory neurons. This results in the neurons becoming excited, and pain signals are sent to the spinal cord and brain. In the case of inflammation, agents like prostaglandins make TRPV1 more sensitive by lowering its activation threshold, which leads to hyperalgesia and long-lasting pain. Medications that inhibit TRPV1 are able to lessen pain signal transmission and are currently being researched for nerve pain, arthritis, and chronic cough.[64,65]

TRPA1

ARTtarget besides TRPV1. These channels are noted to be activated by a large variety of irritants such as allyl isothiocyanate, allicin, and cinnamaldehyde. Besides that, several endogenous molecules released during inflammation and oxidative stress have been identified to be linked to TRPA1 activation, thus clearly indicating a possible function of this channel in pain and nociception.[66]

Accumulating evidence from animal models using a number of experiments points out the effectiveness of TRPA1 antagonists like HC-030031, A-967079, and AMG0902 in the treatment of neuropathic pain in human subjects. The combined supplementation of CHEM-5861528 and streptozotocin to rats was found to prevent intraepidermal nerve fiber loss and attenuated pain. Up to now, GRC-17536 developed by Glenmark is the sole TRPA1 antagonist that has completed phase II clinical trials.[67] It significantly reduced the pain in non-denervation patients having painful diabetic polyneuropathy without any adverse effects.[68]

Due to pharmacokinetics and bioavailability issues, GRC-17536 was terminated before entering phase III trials. Also, it showed poor pharmaceutical characteristics in terms of lipophilicity, bulky structure, and poor solubility. Amgen came up with AMG9090, a partial agonist at rTRPA1 and an antagonist of hTRPA1, which was one of the candidate molecules among a class of species-specific TRPA1 modulators. Orion Corporation produced ODM-108 as a negative allosteric modulator of TRPA1, it could not proceed to phase II clinical trials due to the complexity of its pharmacokinetic outcomes.[69,70]

Mechanism of Action

The TRPA1 serves as a detector for harmful substances and reactive chemicals in the environment. It gets triggered by compounds like mustard oil, garlic derivatives, cigarette smoke, and pollutants. When activated, it permits the entry of Ca^{2+} into nociceptor neurons, resulting in pain, inflammation, and irritation.[71] Apart from this, TRPA1 also promotes the release of neuropeptides that facilitate neurogenic inflammation. Due to its involvement in inflammatory pain, migraine, and respiratory irritation, TRPA1 inhibitors are currently under consideration as pain-relieving and anti-inflammatory agents.[72]

TRPM8

Human studies have shown that a natural variation that causes lower levels of the TRPM8 gene is associated with a lower risk of migraine and less sensitivity to cold pain. Based on this insight, TRPM8 antagonists which block the

receptor can potentially be used as a therapy for migraine and cold-induced pain.[73] It is worthy to note that TRPM8, like TRPV1, also exerted a basal activation tone. It has been reported that antagonists of TRPM8 channels induce mild hypothermia from which the permitted use of these drugs in clinics has not been constrained. Two TRPM8 antagonist drugs, PF-05105679 and AMG-333 are already in clinical trials which have been found to reduce pain sensation in the cold pressor test. A few participants of clinical trials reported that they felt "hot in the mouth" after being administered with PF-05105679 while AMG-333 induced mild side effects (grade 1) in a few volunteers. Furthermore, animal experiments with KRP-2529 and RQ-00434739 (TRPM8 antagonists) demonstrated that these compounds showed potential as therapeutics in alleviating bladder hyperactivity due to chronic inflammation, however, clinical trials of their use in humans are not yet available. Moreover, apart from TRPM8 antagonists, TRPM8 agonists such as DIPA (di-isopropyl-phosphinoyl-alkane) and WS-12 also have the potential of exerting analgesic effects.[74] DIPA was observed to increase the occurrence of rapid, sharp pain-like contractions in the distal colon in human subjects. In addition, TRPM8 agonists have also been indicated to help keep the corneal moisture of patients with dry eye disease Recently, new thiazole derivatives have been designed, synthesized, and biologically evaluated as novel TRPM8 antagonists. An assay has also been developed to facilitate the rapid screening of TRPM8 antagonists by automating patch clamp electrophysiology combined with virtual screening. Using this method, nebivolol emerged as a potential TRPM8 inhibitor, and making changes to its structure could be the basis for novel TRPM8 blocker development.[75]

Mechanism of Action

TRPM8 is actually referred to as the cold receptor. It gets turned on by cold temperatures and substances that produce a cooling sensation like menthol. Once TRPM8 is triggered, it slides open and permits the entry of Ca^{2+} and Na^{+} ions into sensory neurons, thereby making signals that are interpreted as cold sensation. However, in disease states, overactivation may cause an increase in cold sensitivity and neuropathic pain. Changing the activity of TRPM8 could possibly be used for treating prostate cancer as well since the channel is very much present in prostate tissue.[76,77]

Clinical Applications of TRP Channels (TRPV1, TRPM8, and TRPA1)

Transient Receptor Potential (TRP) channels are a family of non-selective cation channels involved in detecting thermal, chemical, and mechanical stimuli. Among them, TRPV1, TRPM8, and TRPA1 are widely studied because of their important role in pain perception, inflammation, and sensory signaling. Due to their involvement in many pathological conditions, these channels have become promising targets for drug development in several clinical fields.

TRPV1

TRPV1 is commonly known as the capsaicin receptor and is activated by high temperature, acidic conditions, and chemical compounds such as capsaicin. This channel is mainly expressed in sensory neurons responsible for detecting painful stimuli.[78] Clinically, TRPV1 is an important target for the treatment of neuropathic pain, inflammatory pain, and arthritis. Topical preparations containing capsaicin are widely used to treat conditions such as post-herpetic neuralgia and diabetic neuropathy. Continuous activation of TRPV1 leads to desensitization of pain-sensing neurons, which helps reduce pain perception. TRPV1 antagonists are also being investigated for the treatment of migraine and chronic inflammatory disorders.[79]

TRPM8

TRPM8 is known as the cold and menthol receptor because it is activated by cold temperatures and cooling compounds such as menthol. This channel is expressed in peripheral sensory neurons and plays an important role in temperature

sensation and pain modulation.[81] In clinical practice, TRPM8 agonists are used to produce a cooling sensation that can relieve muscle pain and minor injuries. TRPM8 is also being investigated as a potential therapeutic target in neuropathic pain and migraine. Additionally, TRPM8 is highly expressed in certain cancers, especially prostate cancer, making it a potential biomarker and drug target in oncology.[81,82]

TRPA1

TRPA1 is activated by a wide range of chemical irritants, environmental pollutants, and endogenous inflammatory mediators. It is expressed in nociceptive neurons and plays a major role in detecting harmful chemical stimuli. TRPA1 is strongly associated with inflammatory pain, chronic cough, and respiratory diseases.[83] Activation of TRPA1 in airway sensory nerves can trigger coughing and airway irritation, which is why TRPA1 antagonists are being explored for the treatment of chronic cough and asthma. In addition, TRPA1 contributes to migraine and neuropathic pain through the release of inflammatory neuropeptides. Blocking TRPA1 activity may therefore provide a new strategy for treating chronic pain and inflammatory conditions.[84]

Challenges of TRP Channels

TRPV1, TRPM8, and TRPA1, in particular, have the potential to be therapeutic targets. However, there are a number of challenges that prevent these from being clinically and successfully used in drug development.

1. Lack of Selectivity

Since many TRP channels feature similar structures, there is a considerable challenge in developing drugs that exclusively target a specific channel without simultaneously impacting others. Issues around the lack of selective targeting often result in side effects that may be undesirable.[85]

2. Adverse Side Effects

Pharmaceuticals directed at TRP channels have the potential for side effects since these channels are ubiquitous in various tissues. For instance, certain TRPV1 antagonists aimed at pain control have been reported to cause loss of heat sensation and an increase in body temperature (hyperthermia).[86]

3. Complex Physiological Roles

TRP channels participate in diverse physiological processes such as controlling body temperature, and mediating inflammation and senses. Therefore, drug interventions that either inhibit or stimulate these channels might lead to aberrations in the normal body operations, presenting a significant hurdle in therapeutic design.[87]

4. Redundant Signaling Pathways

It's worth noting that various TRP channels are capable of mutual compensation within the sensory transmitting routes. When one channel is inhibited, other channels may continue to convey the pain stimulus, thereby possibly diminishing the impact of TRP channel-targeted medicines.[88]

5. Limited Clinical Trial Success

While plenty of TRP modulators demonstrated their potential in animal experiments, only a handful has made it to clinical trial phases and even fewer have become successful. Among the challenges during drug development, toxic effects, unsatisfactory pharmacokinetics, and ineffectiveness are usually the main reasons for failures.[89]

6. Tissue-Sp ecific Expression

TRP channels can be found in different body organs like skin, brain, lungs, and bladder. Producing drugs that would selectively operate in one organ without causing the impact of others is imagining a major challenge.[90]

7. Incomplete Understanding of Mechanisms

Extensive studies notwithstanding, molecular mechanisms and pathways of TRP channels in most of the pathological conditions have remained ambiguous. This containment of knowledge has a direct impact on the ability to create specific therapies.[91]

Future directions

Future research on **TRPV1, TRPM8, and TRPA1** focuses on improving their therapeutic potential and overcoming current limitations in drug development. These channels are involved in pain perception, inflammation, temperature sensing, and various pathological conditions, making them promising targets for future medical therapies.[92] One important direction is the **development of highly selective modulators**. Scientists are working to design drugs that specifically target individual TRP channels without affecting other ion channels. Improved selectivity may reduce unwanted side effects and increase therapeutic effectiveness in treating chronic pain and inflammatory disorders.[93.94]

Another promising area is **personalized medicine**. Genetic studies of TRP channel variations may help identify patients who respond better to TRP-targeted therapies. This approach could allow clinicians to tailor treatments based on a patient's genetic profile, improving clinical outcomes.[95] Research is also focusing on **novel drug delivery systems**. Advanced delivery methods such as nanoparticle-based formulations or targeted topical therapies may help deliver TRP modulators directly to affected tissues, reducing systemic side effects and increasing drug efficiency.[96]

Additionally, TRP channels are being investigated as biomarkers for disease diagnosis and progression, especially in neurological disorders, cancer, and inflammatory diseases. Understanding their expression patterns may help detect diseases at earlier stages and monitor treatment responses.[97,98]

CONCLUSION

Transient receptor potential (TRP) channels represent a significant group of ion channels that largely contribute to the detection and transmission of sensory signals in the human body. These channels participate in the sensing of temperature changes, mechanical stress, and chemical stimuli, and as a result, play an important part in physiological phenomena such as pain perception, inflammation, and cellular signaling. Out of the multiple types of TRP channels, TRPV1, TRPM8, and TRPA1 are the ones that have been mostly studied for their shared and individual roles in the nociceptive and sensory physiology processes. These channels essentially serve as molecular sensors that are responsible for the conversion of external stimuli such as heat, cold, and chemical irritants to electrical impulses that the nervous system can interpret.

In the last several decades, studies have found that abnormal or continuous activation of TRP channels can cause or contribute to many pathological conditions, such as chronic pain, neuropathic pain, inflammatory disorders, respiratory diseases, and migraine. Due to their implication in these disease mechanisms, TRP channels are now considered among the most interesting targets for the development of new therapeutic drugs. Drugs that either activate or inhibit TRP channels have been shown to be effective in treating pain and inflammation. Therapeutic agents that interact with

TRPV1, TRPM8, and TRPA1 are currently being tested for their effectiveness in lowering pain, controlling inflammation, and modulating the activity of sensory nerves.

Although TRP channels hold great promise for the therapy of various conditions, a number of obstacles need to be addressed before these findings can be turned into treatment options that actually work in clinics. Factors such as insufficient drug selectivity, adverse side effects, and the intricate functions of these channels in the body can all pose challenges to drug development. Besides, since TRP channels are present in a number of different tissues, therapies need to be carefully designed so as not to cause off-target effects.

REFRENCES

1. Mulier M, Vriens J, Voets T. TRP channel pores and local calcium signals. Cell Calcium, 2017; 66: 19-24.
2. Voets T, Vriens J, Vennekens R. Targeting TRP channels - valuable alternatives to combat pain, lower urinary tract disorders, and type 2 diabetes? Trends Phar- macol Sci., 2019; 40: 669-683.
3. Bon RS, Wright DJ, Beech DJ, Sukumar P. Pharmacology of TRPC channels and its potential in cardiovascular and metabolic medicine. Annu Rev Pharmacol Toxicol, 202; 62: 427-446.
4. Samanta A, Hughes TET, Moiseenkova-Bell VY. Transient receptor potential (TRP) channels. Subcell Biochem, 2018; 87: 141-165.
5. Yin Y, Wu M, Zubcevic L, et al. Structure of the cold- and menthol-sensing ion channel TRPM8. Science, 2018; 359: 237-241.
6. Vangeel L, Voets T. Transient receptor potential channels and calcium signaling. Cold Spring Harb Perspect Biol, 2019; 11: a035048.
7. Dhakal S, Lee Y. Transient receptor potential channels and metabolism. Mol Cells, 2019; 42: 569-578.
8. Huang Q, Wang X, Lin X, et al. The role of transient receptor potential channels in blood-brain barrier dysfunction after ischemic stroke. Biomed Pharmacother, 2020; 131: 110647.
9. Sharma S, Hopkins CR. Review of transient receptor potential canonical (TRPC5) channel modulators and diseases. J Med Chem, 2019; 62: 7589-7602.
10. Himmel NJ, Cox DN. Transient receptor potential channels: current perspectives on evolution, structure, function and nomenclature. Proc Biol Sci., 2020; 287: 20201309.
11. Yang D, Kim J. Emerging role of transient receptor potential (TRP) channels in cancer progression. BMB Rep., 2020; 53: 125-132.
12. Tsagareli MG, Nozadze I. An overview on transient receptor potential channels superfamily. Behav Pharmacol, 2020; 31: 413-434.
13. Yang HH, Jhang JF, Hsu YH, et al. smaller bladder capacity and stronger blad- der contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4. Sci Rep., 2021; 11: 5200.
14. Zhu S, Ye H, Xu X, et al. Involvement of TRPC7-AS1 expression in hepatitis B virus-related hepatocellular carcinoma. J Oncol, 2021; 2021: 8114327.
15. Rajan S, Schremmer C, Weber J, et al. Ca^{2+}signaling by TRPV4 channels in respiratory function and disease. Cells, 2021; 10: 822.
16. Bogdanova E, Beresneva O, Galkina O, et al. Myocardial hypertrophy and fibro- sis are associated with cardiomyocyte beta-catenin and TRPC6/Calcineurin/ NFAT signaling in spontaneously hypertensive rats with 5/6 nephrectomy. Int J Mol Sci., 2021; 22: 4645.

17. Deng Z, Maksaev G, Rau M, et al. Gating of human TRPV3 in a lipid bilayer. Nat Struct Mol Biol, 2020; 27: 635-644.
18. Chinigò G, Fiorio Pla A, Gkika D. TRP channels and small GTPases Interplay in the main hallmarks of metastatic cancer. Front Pharmacol, 2020; 11: 581455.
19. Singh R, Adhya P, Sharma SS. Redox-sensitive TRP channels: a promising pharmacological target in chemotherapy-induced peripheral neuropathy. Expert Opin 7er Targets, 2021; 25: 529-545.
20. Turlova E, Wong R, Xu B, et al. TRPM7 mediates neuronal cell death upstream of calcium/calmodulin-dependent protein kinase II and calcineurin mechanism in neonatal hypoxic-ischemic brain injury. Transl Stroke Res, 2021; 12: 164-184.
21. Herz JM, Buated W, Thomsen W, Mori Y. Novel TRPA1 antagonists are multi- modal blockers of human TRPA1 channels: drug candidates for treatment of familial episodic pain syndrome (FEPS). FASEB J., 2020; 34: 1-1.
22. Miyamoto S, Iida S, Miyashita T, et al. Mechanism of chronic pain of symptomatic hip osteoarthritis by association of its distribution, nociceptive, neuropathic, nociplastic, or mixed-pain screening, and the prevalence of lumbar spinal steno- sis: a cross-sectional study J Pain, 2021; 38: 77-87.
23. Cohen ML. Proposed clinical criteria for nociplastic pain in the musculoskeletal system are flawed. Pain, 2022; 163: e606-e607.
24. Sapio MR, Iadarola MJ, Loyd Pierson AJ, et al. Dynorphin and enkephalin opioid peptides and transcripts in spinal cord and dorsal root ganglion during peripheral inflammatory hyperalgesia and Allodynia. J Pain, 2020; 21: 988-1004.
25. Dieterle M, Zurbriggen L, Mauermann E, et al. Pain response to cannabidiol in opioid-induced hyperalgesia, acute nociceptive pain, and allodynia using a model mimicking acute pain in healthy adults in a randomized trial (CANAB II). Pain, 2022; 163: 1919-1928.
26. Aleixandre-Carrera F, Engelmayer N, Ares-Suárez D, et al. Optical assessment of nociceptive TRP channel function at the peripheral nerve terminal. Int J Mol Sci., 2021; 22: 481.
27. Iannone LF, De Logu F, Geppetti P, De Cesaris F. The role of TRP ion channels in migraine and headache. Neurosci Lett., 2022; 768: 136380.
28. Fakhri S, Jafarian S, Majnooni MB, et al. Anti-nociceptive and anti-inflammatory activities of the essential oil isolated from Cupressus arizonica Greene fruits. Korean J Pain, 2022; 35: 33-42.
29. Dux M, Rosta J, Messlinger K. TRP channels in the focus of trigeminal nociceptor sensitization contributing to primary headaches. Int J Mol Sci., 2020; 21: 342.
30. Bamps D, Vriens J, de Hoon J, Voets T. TRP channel cooperation for nociception: therapeutic opportunities. Annu Rev Pharmacol Toxicol, 2021; 61: 655-677.
31. Arsenault P, Chiche D, Brown W, et al. NEO6860, modality-selective TRPV1 antagonist: a randomized, controlled, proof-of-concept trial in patients with osteoarthritis knee pain. Pain Rep., 2018; 3:e696.
32. International Association for the Study of Pain, IASP terminology update on pain classification, 2017.
33. Kosek E, Cohen M, Baron R, et al., Chronic nociplastic pain conditions. The Lancet, 2021.
34. Woolf CJ., Central sensitization: Implications for pain diagnosis and treatment. Pain, 2011.
35. International Association for the Study of Pain (IASP). Definition of neuropathic pain (2011, updated terminology).
36. The Lancet Neurology – Colloca L, Ludman T, Bouhassira D, et al., Neuropathic pain, 2017.

37. Pain – Treede RD, Jensen TS, Campbell JN, et al., Neuropathic pain: Redefinition and grading system, 2008.
38. Alcaraz MJ, Guillén MI, Ferrándiz ML. Emerging therapeutic agents in osteo- arthritis. Biochem Pharmacol, 2019; 165: 4-16.
39. Bryk M, Starowicz K. Cannabinoid-based therapy as a future for joint degeneration. Focus on the role of CB_2 receptor in the arthritis progression and pain: an updated review. Pharmacol Rep., 2021; 73: 681-699.
40. Grässel S, Muschter D. Recent advances in the treatment of osteoarthritis. F 1000Res, 2020; 9: 325.
41. Kym PR, Kort ME, Hutchins CW. Analgesic potential of TRPV1 antagonists. Biochem Pharmacol, 2009; 78: 211-216.
42. Lee YW, Won C-, Jung K, et al. Efficacy and safety of PAC-14028 cream – a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild- to-moderate atopic dermatitis: a phaseIIb randomized trial. Br J Dermatol, 2019; 180: 1030-1038.
43. Damann N, Bahrenberg G, Stockhausen H, et al. In vitro characterization of the thermoneutral transient receptor potential vanilloid-1 (TRPV1) inhibitor GRTE16523. Eur J Pharmacol, 2020; 871: 172934.
44. Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol Med, 2009; 15: 14-22.
45. De Petrocellis L, Moriello AS. Modulation of the TRPV1 channel: current clinical trials and recent patents with focus on neurological conditions. Recent Pat CNS Drug Discov, 2013; 8: 180-204.
46. Khare P, Mahajan N, Singh DP, et al. Allicin, a dietary trpa1 agonist, prevents high fat diet-induced dysregulation of gut hormones and associated complications. Food Funct, 2021; 12: 11526-11536.
47. Sodhi RK, Singh R, Bansal Y, et al. Intersections in neuropsychiatric and metabolic disorders: possible role of TRPA1 channels. Front Endocrinol, 2021; 12: 771575.
48. Achanta S, Jordt SE. Transient receptor potential channels in pulmonary chemical injuries and as countermeasure targets. Ann N Y Acad Sci., 2020; 1480: 73-103.
49. Chen H, Terrett JA. Transient receptor potential ankyrin 1 (TRPA1) antagonist: a patent review (2015-2019). Expert Opin 7er Pat., 2020; 30: 643-657.
50. Pinheiro FDV, Villarinho JG, Silva CR, et al. The involvement of the TRPA1 receptor in a mouse model of sympathetically maintained neuropathic pain. Eur J Pharmacol, 2015; 747: 105-113.
51. Fernández-Carvajal A, González-Muñiz R, Fernández-Ballester G, Ferrer- Montiel A. Investigational drugs in early phase clinical trials targeting thermo- transient receptor potential (thermoTRP) channels. Expert Opin Investing Drugs, 2020; 29: 1209-1222.
52. Yoon HJ, Kim J, Yang JM, et al. Topical TRPM8 agonist for relieving neuro- pathic ocular pain in patients with dry Eye: A Pilot Study. J Clin Med, 2021; 10: 250.
53. Sugino S, Inoue K, Kobayashi R, et al. Association between the cool temperature-dependent suppression of colonic peristalsis and transient receptor potential melastatin 8 activations in both a randomized clinical trial and an animal model. J Neurogastroenterol Motil, 2022; 28: 693-705.
54. Marsicano V, Arcadi A, Bianchini G, Tomassetti M, Aramini A. Design, synthesis and biological evaluation of new thiazole scaffolds as potential TRPM8 antagonists. Bioorg Med Chem Lett, 2021; 52: 128392.
55. Jahanfar F, Sadofsky L, Morice A, D'Amico M. Nebivolol as a potent TRPM8 channel blocker: A Drug-screening approach through automated patch clamping and ligand-based virtual screening. Membranes, 2022; 12: 954.
56. Logashina YA, Palikova YA, Palikov VA, et al. Anti-inflammatory and analgesic effects of TRPV1 polypeptide

modulator APHC3 in models of Osteo- and rheumatoid arthritis. Mar Drugs, 2021; 19: 39.

57. Yang Z, Zhou Z, Si T, et al. High throughput confined migration microfluidic device for drug screening. Small, 2023; 19: e2207194.
58. Andrei C, Mihai DP, Zanfirescu A, Nitulescu GM, Negres S. In silico drug repurposing framework predicts repaglinide, agomelatine and protokylol as TRPV1 modulators with analgesic activity. Pharmaceutics, 2022; 14: 2563.
59. Heber S, Fischer MJM. Non-Analgesic symptomatic or disease-modifying potential of TRPA1. Med Sci., 2019; 7: 99.
60. Yuan J, Liang X, Zhou W, et al. TRPA1 promotes cisplatin-induced nephrotoxicity through inflammation mediated by the MAPK/NF-B signaling pathway. Ann Transl Med, 2021; 9: 1578.
61. Lindsay CD, Timperley CM. TRPA1 and issues relating to animal model selection for extrapolating toxicity data to humans. Hum Exp Toxicol, 2020; 39: 14-36.
62. Khara LS, Ali DW. The endocannabinoid system's involvement in motor development relies on cannabinoid receptors, TRP channels, and Sonic Hedgehog signaling. Physiol Rep., 2023; 11: e15565.
63. Bonache MÁ, Martín-Escura C, de la Torre Martínez R, et al. Highly functionalized lactams and 2-ketopiperazines as TRPM8 antagonists with antiallodynic activity. Sci Rep, 2020; 10: 14154.
64. Fernández-Carvajal A, González-Muñiz R, Fernández-Ballester G, Ferrer- Montiel A. Investigational drugs in early phase clinical trials targeting thermo- transient receptor potential (thermoTRP) channels. Expert Opin Investing Drugs, 2020; 29: 1209-1222.
65. Yoon HJ, Kim J, Yang JM, et al. Topical TRPM8 agonist for relieving neuro- pathic ocular pain in patients with dry Eye: A Pilot Study. J Clin Med, 2021; 10: 250.
66. Sugino S, Inoue K, Kobayashi R, et al. Association between the cool temperature-dependent suppression of colonic peristalsis and transient receptor potential melastatin 8 activations in both a randomized clinical trial and an animal model. J Neurogastroenterol Motil, 2022; 28: 693-705.
67. Marsicano V, Arcadi A, Bianchini G, Tomassetti M, Aramini A. Design, synthesis and biological evaluation of new thiazole scaffolds as potential TRPM8 antagonists. Bioorg Med Chem Lett, 2021; 52: 128392.
68. Jahanfar F, Sadofsky L, Morice A, D'Amico M. Nebivolol as a potent TRPM8 channel blocker: A Drug-screening approach through automated patch clamping and ligand-based virtual screening. Membranes, 2022; 12: 954.
69. Logashina YA, Palikova YA, Palikov VA, et al. Anti-inflammatory and analgesic effects of TRPV1 polypeptide modulator APHC3 in models of Osteo- and rheumatoid arthritis. Mar Drugs, 2021; 19: 39.
70. Yang Z, Zhou Z, Si T, et al. High throughput confined migration microfluidic device for drug screening. Small, 2023; 19: e2207194.
71. Andrei C, Mihai DP, Zanfirescu A, Nitulescu GM, Negres S. In silico drug repurposing framework predicts repaglinide, agomelatine and protokylol as TRPV1 modulators with analgesic activity. Pharmaceutics, 2022; 14: 2563.
72. Heber S, Fischer MJM. Non-Analgesic symptomatic or disease-modifying potential of TRPA1. Med Sci., 2019; 7: 99.
73. Yuan J, Liang X, Zhou W, et al. TRPA1 promotes cisplatin-induced nephrotoxicity through inflammation mediated by the MAPK/NF-B signaling pathway Ann Transl Med, 2021; 9: 1578.
74. Lindsay CD, Timperley CM. TRPA1 and issues relating to animal model selection for extrapolating toxicity data to

humans. Hum Exp Toxicol, 2020; 39: 14-36.

75. Khara LS, Ali DW. The endocannabinoid system's involvement in motor development relies on cannabinoid receptors, TRP channels, and Sonic Hedgehog signaling. Physiol Rep, 2023; 11: e15565.
76. Bonache MÁ, Martín-Escura C, de la Torre Martínez R, et al. Highly functionalized -lactams and 2-ketopiperazines as TRPM8 antagonists with antiallodynic activity. Sci Rep, 2020; 10: 14154.
77. Wong GY, Gavva NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Res. Rev. 2009;60(1):267–77. doi: 10.1016/j.brainresrev, 2008; 12.006.
78. Szallasi A, Sheta M. Targeting TRPV1 for pain relief limits losers and laurels. Expert Opin. Investig. Drugs, 2012; 21(9): 1351–69. doi: 10.1517/13543784.2012.704021.
79. Blumberg PM, Pearce LV, Lee J. TRPV1 activation is not an all-or-none event: TRPV1 partial agonism/antagonism and its regulatory modulation. Curr. Top. Med. Chem, 2011; 11(17): 2151–8. doi: 10.2174/156802611796904825.
80. Steiner AA, Turek VF, Almeida MC, Burmeister JJ, Oliveira DL, Roberts JL, Bannon AW, Norman MH, Louis JC, Treanor JJ, Gavva NR, Romanovsky AA. Nonthermal activation of transient receptor potential vanilloid-1 channels in abdominal viscera tonically inhibits autonomic cold-defense effectors. J. Neurosci, 2007; 27(28): 7459–68. doi: 10.1523/JNEUROSCI.1483-07.2007.
81. Gavva NR, Bannon AW, Hovland DNJr, Lehto SG, Klionsky L, Surapaneni S, Immke DC, Henley C, Arik L, Bak A, Davis J, Ernst N, Hever G, Kuang R, Shi L, Tamir R, Wang J, Wang W, Zajic G, Zhu D, Norman MH, Louis JC, Magal E, Treanor JJ. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J. Pharmacol. Exp. Ther, 2007; 323(1): 128–37. doi: 10.1124/jpet.107.125674.
82. Doherty EM, Fotsch C, Bannon AW, Bo Y, Chen N, Dominguez C, Falsey J, Gavva NR, Katon J, Nixey T, Ognyanov VI, Pettus L, Rzasa RM, Stec M, Surapaneni S, Tamir R, Zhu J, Treanor JJ, Norman MH. Novel vanilloid receptor-1 antagonists 2.Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. J. Med. Chem, 2007; 50(15): 3515–27. doi: 10.1021/jm070190p.
83. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, LuisHannan S, Lappin SC, Egerton J, Smith GD, Worby A, Howett L, Owen D, Nasir S, Davies CH, Thompson M, Wyman PA, Randall AD, Davis JB. Identification and characterisation of SB-366791 a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology, 2004; 46(1): 133–49. doi: 10.1016/s0028-3908(03)00305-8.
84. Cui M, Honore P, Zhong C, Gauvin D, Mikusa J, Hernandez G, Chandran P, Gomtsyan A, Brown B, Bayburt EK, Marsh K, Bianchi B, McDonald H, Niforatos W, Neelands TR, Moreland RB, Decker MW, Lee CH, Sullivan JP, Faltynek CR. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J. Neurosci, 2006; 26(37): 9385–93. doi: 10.1523/JNEUROSCI.1246-06.2006.
85. Swanson DM, Dubin AE, Shah C, Nasser N, Chang L, Dax SL, Jetter M, Breitenbucher JG, Liu C, Mazur C, Lord B, Gonzales L, Hoey K, Rizzolio M, Bogenstaetter M, Codd EE, Lee DH, Zhang SP, Chaplan SR, Carruthers NI. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem, 2005; 48(6): 1857–72. doi: 10.1021/jm0495071.
86. Pomonis JD, Harrison JE, Mark L, Bristol DR, Valenzano KJ, Walker K. N-(4-Tertiarybutylphenyl)-4-(3-cholorphyridin-2-yl) tetrahydropyrazine -1(2H)-carbox-amide (BCTC a novel orally effective vanilloid receptor 1

antagonist with analgesic properties.II in vivo characterization in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther, 2003; 306(1): 387–93. doi: 10.1124/jpet.102.046268.

87. Khairatkar-Joshi N, Szallasi A. TRPV1 antagonists: the challenges for therapeutic targeting. Trends Mol. Med, 2009; 15(1): 14–22. doi: 10.1016/j.molmed.2008.11.004.
88. Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, Banfield C, Davar G. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain, 2008; 136(1-2): 202–10. doi: 10.1016/j.pain.2008.01.024.
89. Rowbotham MC, Nothaft W, Duan WR, Wang Y, Faltynek C, McGaraughty S, Chu KL, Svensson P. Oral and cutaneous thermosensory profile of selective TRPV1 inhibition by ABT-102 in a randomized healthy volunteer trial. Pain, 2011; 152(5): 1192–200. doi: 10.1016/j.pain.2011.01.051.
90. Krarup AL, Ny L, Astrand M, Bajor A, Hvid-Jensen F, Hansen MB, Simren M, Funch-Jensen P, Drewes AM. Randomised clinical trial the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol. Ther, 2011; 33(10): 1113–22. doi: 10.1111/j.1365-2036.2011.04629.x.
91. Lehto SG, Tamir R, Deng H, Klionsky L, Kuang R, Le A, Lee D, Louis JC, Magal E, Manning BH, Rubino J, Surapaneni S, Tamayo N, Wang T, Wang J, Wang W, Youngblood B, Zhang M, Zhu D, Norman MH, Gavva NR. Antihyperalgesic effects of (RE)-N-(2-hydroxy-2-3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(trifluorom ethyl)phenyl)-acrylamide (AMG8562 a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J. Pharmacol. Exp. Ther, 2008; 326(1): 218–29. doi: 10.1124/jpet.107.132233.
92. Garami A, Shimansky YP, Pakai E, Oliveira DL, Gavva NR, Romanovsky AA. Contributions of different modes of TRPV1 activation to TRPV1 antagonist-induced hyperthermia. J. Neurosci, 2010; 30(4): 1435–40. doi: 10.1523/JNEUROSCI.5150-09.2010.
93. Reilly RM, McDonald HA, Puttfarcken PS, Joshi SK, Lewis L, Pai M, Franklin PH, Segreti JA, Neelands TR, Han P, Chen J, Mantyh PW, Ghilardi JR, Turner TM, Voight EA, Daanen JF, Schmidt RG, Gomtsyan A, Kort ME, Faltynek CR, Kym PR. Pharmacology of modality-specific transient receptor potential vanilloid-1 antagonists that do not alter body temperature. J. Pharmacol. Exp. Ther, 2012; 342(2): 416–28. doi: 10.1124/jpet.111.190314.
94. Ro JY, Lee JS, Zhang Y. Activation of TRPV1 and TRPA1 leads to muscle nociception and mechanical hyperalgesia. Pain, 2009; 144(3): 270–7. doi: 10.1016/j.pain.2009.04.021.
95. McNamara CR, Mandel-Brehm J, Bautista DM, Siemens J, Deranian KL, Zhao M, Hayward NJ, Chong JA, Julius D, Moran MM, Fanger CM. TRPA1 mediates formalin-induced pain. Proc. Natl. Acad. Sci. U.S.A., 2007; 104(33): 13525–30. doi: 10.1073/pnas.0705924104.
96. McGaraughty S, Chu KL, Perner RJ, Didomenico S, Kort ME, Kym PR. TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons in uninjured osteoarthritic and inflamed rats. Mol. Pain, 2010; 6: 14. doi: 10.1186/1744-8069-6-14.
97. Mukhopadhyay I, Gomes P, Aranake S, Shetty M, Karnik P, Damle M, Kuruganti S, Thorat S, Khairatkar-Joshi N. Expression of functional TRPA1 receptor on human lung fibroblast and epithelial cells. J. Recept Signal Transduct. Res, 2011; 31(5): 350–8. doi: 10.3109/10799893.2011.602413.
98. Gijsen HJ, Berthelot D, DeCleyn MA, Geuens I, Brone B, Mercken M. Tricyclic 3-4-dihydropyrimidine-2-thione derivatives as potent TRPA1 antagonists. Bioorg. Med. Chem. Lett, 2012; 22(2): 797–800. doi: 10.1016/j.bmcl.2011.12.068.